Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Positive pivotal BEACON data and imminent BLA submission for risto-cel are the dominant near-term catalysts, though the stock's muted reaction suggests sentiment remains cautious ahead of ASH data and FDA filing.
Beam reported that risto-cel met the primary efficacy endpoint (freedom from severe VOCs for 12 consecutive months) and all primary safety and secondary endpoints in the BEACON Phase 1/2 trial. This de-risks the lead program and supports an imminent BLA submission, a key value-inflection catalyst for the stock.
Beam Therapeutics Press Release (GlobeNewswire)Beam reiterated plans to submit a U.S. BLA for risto-cel to the FDA as early as end of 2026. The filing is a near-term regulatory catalyst that could drive re-rating as it approaches and upon acceptance.
Beam Therapeutics Press Release (GlobeNewswire)Beam will present earlier-cutoff BEACON data in an oral presentation at the ASH Annual Meeting (Dec 12-15, 2026). This is a near-term event that could provide additional durability/safety detail and move the stock depending on reception.
Beam Therapeutics Press Release (GlobeNewswire)Beam reported a Q3 2026 net loss of $134.4 million ($1.28/share) on revenue of $307,000, with $1.0 billion in cash and runway into mid-2029. The update also highlighted BEAM-302 pivotal dosing completion expected in H1 2027 and BEAM-301 proof-of-concept data, framing the broader pipeline narrative.
Beam Therapeutics Q3 2026 ResultsBeam reported initial BEAM-301 Phase 1/2 data showing dose-dependent improvements in fasting tolerance and elimination of starch supplementation in two of three 40 mg patients, with a 60 mg cohort enrolling and FDA engagement planned. Positive but earlier-stage, it supports pipeline optionality.
Beam Therapeutics Press Release